Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTXHYV6)

DTT Name	Voltage-gated L-type calcium channel (L-CaC)
Synonyms	L-type voltage-dependent Ca(2+) channel; L-type Ca2+ channel; L-type Ca(2+) channel
Gene Name	NO-GeName
DTT Type	Successful target	[1]
Related Disease	Angina pectoris [ICD-11: BA40] Hypertension [ICD-11: BA00-BA04] Neuropathy [ICD-11: 8C0Z] Oesophagus motility disorder [ICD-11: DA21]
BioChemical Class	Voltage-gated ion channel
UniProt ID	NOUNIPROTAC
TTD ID	T82266

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DTT

5 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[2]
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[3]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[4]
Otilonium bromide	DM05968	Gastric motility disorder	DA21	Approved	[1]
Levamlodipine	DM92S6N	Hypertension	BA00-BA04	Phase 4	[5]
------------------------------------------------------------------------------------

5 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[6], [7]
Pinaverium bromide	DM7OSHC	Irritable bowel syndrome	DD91.0	Phase 3	[1]
MEM-1003	DMYZU6G	Bipolar disorder	6A60	Phase 2a	[8]
BAY-Y-5959	DMLO18H	Cardiovascular disease	BA00-BE2Z	Phase 2	[9]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[10], [11]
------------------------------------------------------------------------------------

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Furnidipine	DME94QF	Nerve injury	ND56.4	Discontinued in Phase 3	[12]
------------------------------------------------------------------------------------

20 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ajinomoto 1	DMHMVOI	Pain	MG30-MG3Z	Investigative	[3]
Ajinomoto 2	DMZE45V	Pain	MG30-MG3Z	Investigative	[3]
Ajinomoto 3	DMG12AE	Pain	MG30-MG3Z	Investigative	[3]
Bay K 8644	DMRWSGO	Discovery agent	N.A.	Investigative	[11]
Dihydropyridines	DM0W64U	Discovery agent	N.A.	Investigative	[7]
Euro-Celtique 1	DMO3AZ6	Pain	MG30-MG3Z	Investigative	[3]
Euro-Celtique 2	DMJH4BF	Pain	MG30-MG3Z	Investigative	[3]
Euro-Celtique 3	DM8VI3T	Pain	MG30-MG3Z	Investigative	[3]
Euro-Celtique 4	DMO4CEL	Pain	MG30-MG3Z	Investigative	[3]
Neuromed 2	DMSJ6T1	Pain	MG30-MG3Z	Investigative	[3]
Neuromed 5	DMXKT45	Pain	MG30-MG3Z	Investigative	[3]
Ono 1	DMSWI4D	Pain	MG30-MG3Z	Investigative	[3]
Ono 3	DMCG6H8	Pain	MG30-MG3Z	Investigative	[3]
Parke-Davis 1	DMVI8R2	Pain	MG30-MG3Z	Investigative	[3]
Parke-Davis 9	DMMQY42	Pain	MG30-MG3Z	Investigative	[3]
PD173212	DMRBKW6	Pain	MG30-MG3Z	Investigative	[3]
PD176078	DM6XHUZ	Pain	MG30-MG3Z	Investigative	[3]
S 202 791	DMGEHNX	Discovery agent	N.A.	Investigative	[11]
SQ32,910	DML6SIE	Discovery agent	N.A.	Investigative	[11]
[3H](-)devapamil	DM0KGHP	Discovery agent	N.A.	Investigative	[10], [11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Investigative Drug(s)

References

1	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
2	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
6	N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
7	Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66.
8	Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
9	Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.
10	Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
11	Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96.
12	Q-type Ca2+ channels are located closer to secretory sites than L-type channels: functional evidence in chromaffin cells. Pflugers Arch. 1998 Mar;435(4):472-8.